Results
|
|
21.
|
|
|
|
22.
|
|
|
|
23.
|
|
|
|
24.
|
|
|
|
25.
|
|
|
|
26.
|
|
|
|
27.
|
|
|
|
28.
|
|
|
|
29.
|
|
|
|
30.
|
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice]. [electronic resource] by
- Liu, Yanxia
- Zhang, Tongmei
- Gao, Yuan
- Qu, Yang
- Lu, Baohua
- Zhang, Hongmei
- Wang, Qunhui
- Li, Jie
- Hu, Fanbin
- Li, Baolan
Producer: 20200413
In:
Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 22
Availability: No items available.
|
|
|
31.
|
[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations]. [electronic resource] by
- Wang, Qunhui
- Zheng, Hua
- Hu, Fanbin
- Zhang, Hongmei
- Hu, Ying
- Li, Jie
- Zhang, Tongmei
- Liu, Zan
- Lu, Baohua
- Hu, Aimin
- Li, Baolan
Producer: 20170327
In:
Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 19
Availability: No items available.
|
|
|
32.
|
Investigating the mechanism by which SMAD3 induces PAX6 transcription to promote the development of non-small cell lung cancer. [electronic resource] by
- Qian, Zhe
- Zhang, Qiankun
- Hu, Ying
- Zhang, Tongmei
- Li, Jie
- Liu, Zan
- Zheng, Hua
- Gao, Yuan
- Jia, Wenyun
- Hu, Aimin
- Li, Baolan
- Hao, Jiqing
Producer: 20190121
In:
Respiratory research vol. 19
Availability: No items available.
|
|
|
33.
|
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). [electronic resource] by
- Han, Baohui
- Li, Kai
- Zhao, Yizhuo
- Li, Baolan
- Cheng, Ying
- Zhou, Jianying
- Lu, You
- Shi, Yuankai
- Wang, Zhehai
- Jiang, Liyan
- Luo, Yi
- Zhang, Yiping
- Huang, Cheng
- Li, Qiang
- Wu, Guoming
Producer: 20190125
In:
British journal of cancer vol. 118
Availability: No items available.
|
|
|
34.
|
High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer. [electronic resource] by
- Li, Xuebing
- Yang, Yuan
- Zhang, Haiqing
- Yue, Wentao
- Zhang, Tongmei
- Lu, Baohua
- Li, Jie
- Liu, Zan
- Wang, Qunhui
- Gao, Yuan
- Hu, Aimin
- Zhang, Hongmei
- Shi, Heling
- Hu, Fanbin
- Li, Baolan
Producer: 20170119
In:
Cell biochemistry and biophysics vol. 73
Availability: No items available.
|
|
|
35.
|
Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. [electronic resource] by
- Cheng, Ying
- Han, Baohui
- Li, Kai
- Wang, Qiming
- Zhang, Li
- Shi, Jianhua
- Wang, Zhehai
- He, Jianxing
- Shi, Yuankai
- Chen, Weiqiang
- Wang, Xiuwen
- Luo, Yi
- Nan, Kejun
- Jin, Faguang
- Li, Baolan
- Zhu, Jing
Producer: 20210514
In:
Cancer medicine vol. 9
Availability: No items available.
|
|
|
36.
|
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. [electronic resource] by
- Lu, Shun
- Li, Lu
- Luo, Yi
- Zhang, Li
- Wu, Gang
- Chen, Zhiwei
- Huang, Cheng
- Guo, Shuliang
- Zhang, Yiping
- Song, Xiangqun
- Yu, Yongfeng
- Zhou, Caicun
- Li, Wei
- Liao, Meilin
- Li, Baolan
- Xu, Liyan
- Chen, Ping
- Hu, Chunhong
- Hu, Chengping
Producer: 20151030
In:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 10
Availability: No items available.
|
|
|
37.
|
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. [electronic resource] by
- Wang, Jing
- Zhao, Yizhuo
- Wang, Qiming
- Zhang, Li
- Shi, Jianhua
- Wang, Zhehai
- Cheng, Ying
- He, Jianxing
- Shi, Yuankai
- Yu, Hao
- Zhao, Yang
- Chen, Weiqiang
- Luo, Yi
- Wang, Xiuwen
- Nan, Kejun
- Jin, Faguang
- Dong, Jian
- Li, Baolan
- Liu, Zhujun
- Han, Baohui
- Li, Kai
Publication details: Cancer biology & medicine Nov 2018
In:
Cancer biology & medicine vol. 15
Availability: No items available.
|
|
|
38.
|
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC). [electronic resource] by
- Zhou, Caicun
- Huang, Yunchao
- Wang, Donglin
- An, Changshan
- Zhou, Fuxiang
- Li, Yali
- Chen, Gongyan
- Wu, Changping
- He, Jianxing
- Wu, Gang
- Song, Xia
- Gao, Jianfei
- Liu, Wei
- Li, Baolan
- Shi, Jianhua
- Huang, Cheng
- Yu, Jingrui
- Feng, Jueping
- Yue, Hongmei
- Shi, Meiqi
- Xia, Jielai
Producer: 20161213
In:
Clinical lung cancer vol. 17
Availability: No items available.
|
|
|
39.
|
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. [electronic resource] by
- Han, Baohui
- Li, Kai
- Wang, Qiming
- Zhang, Li
- Shi, Jianhua
- Wang, Zhehai
- Cheng, Ying
- He, Jianxing
- Shi, Yuankai
- Zhao, Yizhuo
- Yu, Hao
- Zhao, Yang
- Chen, Weiqiang
- Luo, Yi
- Wu, Lin
- Wang, Xiuwen
- Pirker, Robert
- Nan, Kejun
- Jin, Faguang
- Dong, Jian
- Li, Baolan
- Sun, Yan
Producer: 20191009
In:
JAMA oncology vol. 4
Availability: No items available.
|
|
|
40.
|
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]. [electronic resource] by
- Huang, Yan
- Liu, Yunpeng
- Zhou, Jianying
- Xu, Nong
- Li, Baolan
- Wu, Gang
- Fang, Jian
- Li, Kai
- Liu, Xiaoqing
- Liu, Wei
- Lu, You
- Wang, Mengzhao
- Liu, Wenchao
- Liang, Houjie
- Zhang, Yiping
- Huang, Cheng
- Wang, Shunjin
- Wang, Yajie
- Yu, Shiying
- Chang, Jianhua
- Wang, Zhehai
- Hu, Zhihuang
- Zhang, Li
Producer: 20140113
In:
Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 15
Availability: No items available.
|